OWLT vs SNBR vs IRMD vs MASI vs INVA

For growth investors, Owlet, Inc.

(OWLT) is the stronger pick with 35. 4% revenue growth year-over-year, versus -99. 9% for Sleep Number Corporation (SNBR). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Owlet, Inc. (OWLT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus IRadimed Corporation at 49. 6x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IRadimed Corporation wins at 0. 58x versus Innoviva, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, IRadimed Corporation (IRMD) delivered a total return of +214.

1%, compared to -97. 3% for Sleep Number Corporation (SNBR). Over 10 years, the gap is even starker: IRMD returned +433. 9% versus OWLT's -96. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Sleep Number Corporation's 2. 70β — meaning SNBR is approximately 2039% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 78% for Masimo Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Owlet, Inc.

(OWLT) is pulling ahead at 35. 4% versus -99. 9% for Sleep Number Corporation (SNBR). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -541. 1% for Sleep Number Corporation. Over a 3-year CAGR, IRMD leads at 16. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -39. 6% for Owlet, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -7. 9% for OWLT. At the gross margin level — before operating expenses — IRMD leads at 76. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IRadimed Corporation (IRMD) is the more undervalued stock at a PEG of 0. 58x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 42. 9x for IRadimed Corporation — 31. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OWLT: 311. 5% to $20. 00.

In this comparison, IRMD (1.

3% yield) pays a dividend. OWLT, SNBR, MASI, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, IRadimed Corporation (IRMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

85), 1. 3% yield, +433. 9% 10Y return). Owlet, Inc. (OWLT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IRMD: +433. 9%, OWLT: -96. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OWLT (Healthcare) and SNBR (Consumer Cyclical) and IRMD (Healthcare) and MASI (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OWLT is a mid-cap high-growth stock; SNBR is a small-cap quality compounder stock; IRMD is a small-cap quality compounder stock; MASI is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. IRMD pays a dividend while OWLT, SNBR, MASI, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.